Twist Bioscience Corporation (NASDAQ: TWST) and Biotia has launched today the next-generation SARS-CoV-2 assay for the surveillance of COVID-19. The new highly sensitive nucleic acid hybridization capture-based assay is created to discover all nucleic acid sequences of SARS-CoV-2. This new assay also gives the chance to track how the genetic sequence of the virus is mutating.

NGS assay uses the unique technique of TWST to quickly generate virus-specific panels by DNA synthesis and complete data analysis software and reporting abilities of Biotia. This is the greatest breakthrough as the assay also advanced the knowledge of mutations and how the virus changes once it is transmitted.